{"id":"cd38","name":"CD38","symbol":"CD38","route":"/targets/cd38/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1667","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000004468","uniprot":"https://www.uniprot.org/uniprotkb/P28907/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P28907","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL4660","open-targets":"https://platform.opentargets.org/target/ENSG00000004468","civic":"https://civicdb.org/genes/952/summary","oncokb":"https://www.oncokb.org/gene/CD38","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CD38","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=CD38","depmap":"https://depmap.org/portal/gene/CD38?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000004468-CD38","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/952","omim":"https://www.omim.org/entry/107270"}],"products":[{"id":"daratumumab","name":"Daratumumab","status":"approved","modality":"Monoclonal antibody (anti-CD38)","route":"/drugs/daratumumab/"},{"id":"isatuximab","name":"Isatuximab","status":"approved","modality":"Monoclonal antibody (anti-CD38)","route":"/drugs/isatuximab/"},{"id":"isb-2001","name":"ISB 2001","status":"phase-1","modality":"Trispecific T-cell engager (BCMA x CD38 x CD3)","route":"/drugs/isb-2001/"},{"id":"sg301","name":"SG301","status":"phase-3","modality":"monoclonal antibody (humanised anti-CD38, per the sponsor's description; form not stated in the registry record)","route":"/drugs/sg301/"},{"id":"sti-6129","name":"STI-6129","status":"phase-2","modality":"ADC","route":"/drugs/sti-6129/"}],"trials":[{"id":"nct06868654","name":"China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexame","nct":"NCT06868654","phase":"3","status":"active"},{"id":"nct06868667","name":"Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dex","nct":"NCT06868667","phase":"3","status":"active"},{"id":"majestec-3","name":"MajesTEC-3","nct":"NCT05083169","phase":"3","status":"positive"},{"id":"aquila","name":"AQUILA","nct":"NCT03301220","phase":"3","status":"positive"},{"id":"cepheus","name":"CEPHEUS","nct":"NCT03652064","phase":"3","status":"positive"},{"id":"imroz","name":"IMROZ","nct":"NCT03319667","phase":"3","status":"positive"},{"id":"perseus","name":"PERSEUS","nct":"NCT03710603","phase":"3","status":"positive"},{"id":"nct04649060","name":"Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma","nct":"NCT04649060","phase":"3"},{"id":"cassiopeia","name":"CASSIOPEIA","nct":"NCT02541383","phase":"3","status":"positive"},{"id":"maia","name":"MAIA","nct":"NCT02252172","phase":"3","status":"positive"},{"id":"nct06508983","name":"A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients","nct":"NCT06508983","phase":"3","status":"recruiting"},{"id":"nct06464991","name":"A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)","nct":"NCT06464991","phase":"3","status":"recruiting"},{"id":"nct07391657","name":"A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela","nct":"NCT07391657","phase":"3","status":"recruiting"},{"id":"nct05455320","name":"A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination Wi","nct":"NCT05455320","phase":"3","status":"active"},{"id":"nct06679101","name":"A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethas","nct":"NCT06679101","phase":"3","status":"recruiting"},{"id":"nct05438043","name":"A Study of Daratumumab","nct":"NCT05438043","phase":"3","status":"active"},{"id":"nct05552222","name":"A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal","nct":"NCT05552222","phase":"3","status":"recruiting"},{"id":"nct07742215","name":"A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)","nct":"NCT07742215","phase":"3","status":"recruiting"},{"id":"nct07393282","name":"A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)","nct":"NCT07393282","phase":"3","status":"recruiting"},{"id":"nct06952478","name":"A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone","nct":"NCT06952478","phase":"3","status":"recruiting"},{"id":"nct05623020","name":"A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide","nct":"NCT05623020","phase":"3","status":"recruiting"},{"id":"nct05020236","name":"A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments","nct":"NCT05020236","phase":"3","status":"recruiting"},{"id":"cartitude-6","name":"CARTITUDE-6","nct":"NCT05257083","phase":"3","status":"active"},{"id":"drammatic","name":"DRAMMATIC","nct":"NCT04071457","phase":"3","status":"active"},{"id":"nct04270409","name":"Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma","nct":"NCT04270409","phase":"3","status":"active"},{"id":"nct04975997","name":"Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants ","nct":"NCT04975997","phase":"3","status":"active"},{"id":"nct07764978","name":"Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT","nct":"NCT07764978","phase":"3","status":"recruiting"},{"id":"nct07095452","name":"A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lena","nct":"NCT07095452","phase":"2/3","status":"recruiting"},{"id":"nct03314181","name":"A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractor","nct":"NCT03314181","phase":"2","status":"active"},{"id":"nct06577025","name":"A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Ind","nct":"NCT06577025","phase":"2","status":"active"},{"id":"nct04133636","name":"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Mul","nct":"NCT04133636","phase":"2","status":"active"},{"id":"nct05704049","name":"A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory","nct":"NCT05704049","phase":"2","status":"active"},{"id":"nct04782687","name":"Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma","nct":"NCT04782687","phase":"2","status":"active"},{"id":"nct02773030","name":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple","nct":"NCT02773030","phase":"1/2","status":"active"},{"id":"nct07217184","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM","nct":"NCT07217184","phase":"1/2","status":"active"},{"id":"nct07681596","name":"A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma","nct":"NCT07681596","phase":"1/2","status":"recruiting"},{"id":"nct04973605","name":"A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Darat","nct":"NCT04973605","phase":"1/2","status":"recruiting"},{"id":"nct06953960","name":"A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma ","nct":"NCT06953960","phase":"1/2","status":"recruiting"},{"id":"nct06892522","name":"A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-spe","nct":"NCT06892522","phase":"1/2","status":"recruiting"},{"id":"nct03989414","name":"A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre","nct":"NCT03989414","phase":"1/2","status":"active"},{"id":"nct06119685","name":"IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers","nct":"NCT06119685","phase":"1/2","status":"recruiting"},{"id":"nct04126200","name":"Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple","nct":"NCT04126200","phase":"1/2","status":"active"},{"id":"nct05565807","name":"Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma","nct":"NCT05565807","phase":"1/2","status":"recruiting"},{"id":"nct02343042","name":"Selinexor and Backbone Treatments of Multiple Myeloma Patients","nct":"NCT02343042","phase":"1/2","status":"recruiting"},{"id":"nct05862012","name":"Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)","nct":"NCT05862012","phase":"1","status":"recruiting"}],"pathways":[],"companies":["abbvie","genmab","glenmark","halozyme","hangzhou-sumgen-biotech","johnson-johnson","sanofi","sorrento-therapeutics"],"keyPapers":["paper-cepheus-dara-vrd-natmed-2025","paper-perseus-dara-vrd-transplant-nejm-2024","paper-maia-daratumumab-rd-nejm-2019"],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}